Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2023

Status:

Published in Subsidiary Legislation Supplement
on 30 Nov 2023

No. S 773

Central Provident Fund Act 1953

Central Provident Fund
(Medisave Account Withdrawals)
(Amendment No. 3) Regulations 2023

In exercise of the powers conferred by section 77(1)(j) of the Central Provident Fund Act 1953, the Minister for Manpower, after consulting with the Central Provident Fund Board, makes the following Regulations:

Citation and commencement

1. These Regulations are the Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2023 and come into operation on 1 December 2023.

Amendment of regulation 2

2. In the Central Provident Fund (Medisave Account Withdrawals) Regulations (Rg 17) (called in these Regulations the principal Regulations), in regulation 2(1), after the definition of “member”, insert —

“ “multiple neoplasms” means 2 or more neoplasms that —

(a)	arise from different sites;
(b)	are of a different histology or morphology group; or
(c)	arise from different sites and are of a different histology or morphology group;

“neoplasm” means an abnormal growth of a tissue in a part of the body, that can be benign or malignant;”.

Amendment of regulation 13

3. In the principal Regulations, in regulation 13 —

(a)

in paragraph (7), after “on or after 1 September 2022”, insert “but before 1 December 2023”; and

(b)

after paragraph (7), insert —

“(7A) Subject to regulations 21C and 21D, where a member or a member’s dependant has undergone, on or after 1 December 2023 —

(a)	any cancer scan or diagnostic test, ordered by an approved medical practitioner, as an out‑patient in an approved medical institution; or
(b)	any cancer drug treatment as an out‑patient by an approved medical practitioner in an approved hospital, approved centre or approved clinic,

the amount that may be withdrawn by the member for the payment of such cancer drug treatment, cancer scan or diagnostic test must not exceed the sum specified in the third column of the First Schedule in relation to item 12A or 14 or both, as the case may be.”.

Amendment of First Schedule

4. In the principal Regulations, in the First Schedule —

(a)

in item 12, in the second column, after “1 September 2022”, insert “but before 1 December 2023”;

(b)

after item 12, insert —

“12A.

Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test for any neoplasm during a calendar year —

(a)	where any cancer drug treatment is in respect of multiple neoplasms concurrently

With effect from 1 December 2023

$1,200 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.

(b)	in any other case

With effect from 1 December 2023

$600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.”;

(c)

in item 13(a), (b) and (c), in the second column, after “1 September 2022”, insert “but before 1 December 2023”; and

(d)

after item 13, insert —

“14.	Approved cancer drug administered for the treatment of —

(a)	multiple neoplasms concurrently during a calendar month —

(i)	in respect of each neoplasm treated with only approved cancer drugs listed in the first tier of the CDL

With effect from 1 December 2023

$600 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.

(ii)	in respect of each neoplasm treated with only approved cancer drugs listed in the second tier of the CDL

With effect from 1 December 2023

$1,200 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.

(iii)

in respect of each neoplasm treated with approved cancer drugs listed in both the first tier and the second tier of the CDL

With effect from 1 December 2023

$1,200 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.

(b)	only one neoplasm at a time, and paragraph (a) does not apply to the patient during that calendar month —

(i)	where only approved cancer drugs listed in the first tier of the CDL are administered during that calendar month

With effect from 1 December 2023

$600 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.

(ii)	where only approved cancer drugs listed in the second tier of the CDL are administered during that calendar month

With effect from 1 December 2023

$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.

(iii)

where approved cancer drugs listed in both the first tier and the second tier of the CDL are administered in that calendar month

With effect from 1 December 2023

$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.”.

[G.N. Nos. S 224/2007; S 527/2007; S 731/2007; S 149/2008; S 456/2008; S 682/2008; S 86/2009; S 239/2009; S 523/2009; S 659/2009; S 88/2010; S 118/2010; S 289/2010; S 548/2010; S 367/2011; S 725/2011; S 107/2013; S 482/2013; S 623/2013; S 427/2014; S 872/2014; S 177/2015; S 625/2015; S 377/2016; S 530/2016; S 723/2016; S 340/2017; S 789/2017; S 145/2018; S 341/2018; S 730/2018; S 787/2018; S 397/2019; S 200/2020; S 389/2020; S 855/2020; S 899/2020; S 1089/2020; S 131/2021; S 157/2021; S 315/2021; S 3/2022; S 285/2022; S 716/2022; S 770/2022; S 466/2023; S 652/2023]

Made on 24 November 2023.

NG CHEE KHERN

Permanent Secretary,
Ministry of Manpower,
Singapore.

[Plg&Pol/CPFPol/Legis/CPFSL/2023; AG/LEGIS/SL/36/2020/3 Vol. 1]

(To be presented to Parliament under section 78(2) of the Central Provident Fund Act 1953).

Search within Legislation